Media Kit

Featured News

Announcement

Ophthalmology

BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases

Parkinson's Disease

Announcement

Neurology

BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive trends at 18 months

Announcement

Ophthalmology

BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics

multicolor title graphic for cell & gene the podcast featuring BlueRock Therapeutics

Podcast

Cell & Gene The Podcast | Inside BlueRock Therapeutics' Parkinson's Disease Trial

See All

Media Library

Lab
Headshots
Logos
Offices

Seth Ettenberg, Ph.D.

President and Chief Executive Officer

Natasha Rathee

SVP, Finance

Rebecca Milbury

SVP, People and Culture

Melissa Mudrick

SVP, Quality and Compliance

Ainslie Little, Ph.D.

SVP, Corporate Strategy

Craig Beasley

Chief Technology Officer

Stefan Irion, M.D.

Chief Scientific Officer

Ahmed Enaytellah, M.D., Ph.D.

SVP, Head of Development

Cambridge

New York

Berlin

Toronto

Media Contact

Contact@BlueRockTX.com

Video

B-Roll

B-Roll: Lab 1

B-Roll: Lab 2

B-Roll: Lab 3

B-Roll: Lab 4

B-Roll: Lab 5

B-Roll: Lab 6

B-Roll: PSC-Derived Cardiomyocytes

Explore more with BlueRock

Cell Therapy

Our Programs

Our Pipeline

Careers

Keep up to date with the latest BlueRock Therapeutics news and updates

Follow BlueRock Therapeutics on Linkedin